Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS.

J Pharmacol Exp Ther. 2010 Nov;335(2):362-8. doi: 10.1124/jpet.110.166181.

2.

Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

Celio L, Agustoni F, Testa I, Dotti K, de Braud F.

Tumori. 2012 May-Jun;98(3):279-86. doi: 10.1700/1125.12393. Review.

3.
4.

Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.

Billio A, Morello E, Clarke MJ.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006272. doi: 10.1002/14651858.CD006272.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;12:CD006272.

PMID:
20091591
5.

Emerging drugs for chemotherapy-induced emesis.

Navari RM, Province PS.

Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. Review.

PMID:
16503832
6.

Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.

Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E.

Tumori. 2008 Jul-Aug;94(4):447-52. Review.

7.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Navari RM.

J Support Oncol. 2003 Jul-Aug;1(2):89-103. Review.

PMID:
15352652
8.

Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.

Rojas C, Raje M, Tsukamoto T, Slusher BS.

Eur J Pharmacol. 2014 Jan 5;722:26-37. doi: 10.1016/j.ejphar.2013.08.049. Review.

PMID:
24184669
9.
10.

Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.

Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J.

Eur J Cancer Care (Engl). 2013 Jan;22(1):41-50. doi: 10.1111/j.1365-2354.2012.01353.x. Review.

PMID:
22519361
11.

Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.

Grunberg SM, Koeller JM.

Expert Opin Pharmacother. 2003 Dec;4(12):2297-303. Review.

PMID:
14640928
12.

Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.

Navari RM.

Expert Opin Pharmacother. 2014 Dec;15(17):2599-608. doi: 10.1517/14656566.2014.972366. Review.

PMID:
25323946
13.

An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.

Fabi A, Malaguti P.

Expert Opin Pharmacother. 2013 Apr;14(5):629-41. doi: 10.1517/14656566.2013.771166. Review.

PMID:
23414148
14.

Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.

Navari RM.

Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1577-86. doi: 10.1517/17425250903407289. Review.

PMID:
19929251
15.

Palonosetron: in the prevention of nausea and vomiting.

Yang LP, Scott LJ.

Drugs. 2009 Nov 12;69(16):2257-78. doi: 10.2165/11200980-000000000-00000. Review.

PMID:
19852528
16.

Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.

Navari RM.

Future Oncol. 2006 Oct;2(5):591-602. Review.

PMID:
17026451
17.

New antiemetic drugs.

Roila F, Fatigoni S.

Ann Oncol. 2006 Mar;17 Suppl 2:ii96-100. Review.

PMID:
16608997
18.

The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.

Schwartzberg LS, Jacobs P, Matsouka P, Azevedo W, Pinto A.

Crit Rev Oncol Hematol. 2012 Jul;83(1):59-70. doi: 10.1016/j.critrevonc.2011.09.005. Review.

PMID:
22321726
19.
20.

Emerging treatments in chemotherapy-induced nausea and vomiting.

Grunberg SM, Slusher B, Rugo HS.

Clin Adv Hematol Oncol. 2013 Feb;11(2 Suppl 1):1-18; quiz 2 p following 18. Review.

PMID:
23598819
Items per page

Supplemental Content

Support Center